(TNDM) Tandem Diabetes Care - Overview
Stock: Insulin Pump, Cartridge, Infusion Set, Data Platform, Mobile App
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 67.3% |
| Relative Tail Risk | -12.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.48 |
| Alpha | -64.08 |
| Character TTM | |
|---|---|
| Beta | 1.170 |
| Beta Downside | 1.149 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.07% |
| CAGR/Max DD | -0.28 |
Description: TNDM Tandem Diabetes Care January 18, 2026
Tandem Diabetes Care (NASDAQ:TNDM) develops and sells insulin delivery technologies, most notably the t:slim X2 pump and the Tandem Mobi automated system, alongside consumables such as insulin cartridges and infusion sets. The firm also provides software tools-Device Updater, the Tandem Source data platform, and the Sugarmate mobile app-to integrate pump data with continuous glucose monitors (CGMs). A research partnership with the University of Virginia focuses on next-generation fully automated closed-loop delivery, and the company has operated under its current name since 2008, with headquarters in San Diego.
Key metrics as of FY 2023: total revenue of roughly $1.0 billion, up ~12% year-over-year, and a cash balance of about $500 million, giving the firm flexibility to fund R&D and expand its U.S. market share, which analysts estimate at ~20% of the insulin-pump segment. The primary growth driver is the broader shift toward hybrid closed-loop systems, a trend reinforced by favorable Medicare reimbursement policies and the rising prevalence of Type 1 and Type 2 diabetes worldwide. Competitive pressure remains high, with Medtronic and Insulet as the main rivals, making product differentiation and software integration critical for margin expansion.
For a deeper dive into Tandem’s valuation dynamics and scenario analysis, you may find the ValueRay research hub a useful next stop.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -203.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 1.03 > 1.0 |
| NWC/Revenue: 36.19% < 20% (prev 50.69%; Δ -14.50% < -1%) |
| CFO/TA -0.01 > 3% & CFO -8.79m > Net Income -203.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.7m) vs 12m ago 3.23% < -2% |
| Gross Margin: 53.23% > 18% (prev 0.44%; Δ 5279 % > 0.5%) |
| Asset Turnover: 109.9% > 50% (prev 101.7%; Δ 8.25% > 0%) |
| Interest Coverage Ratio: -25.21 > 6 (EBITDA TTM -179.7m / Interest Expense TTM 7.82m) |
Altman Z'' -5.14
| A: 0.42 (Total Current Assets 616.9m - Total Current Liabilities 252.5m) / Total Assets 874.7m |
| B: -1.43 (Retained Earnings -1.25b / Total Assets 874.7m) |
| C: -0.22 (EBIT TTM -197.1m / Avg Total Assets 916.2m) |
| D: -1.68 (Book Value of Equity -1.25b / Total Liabilities 741.7m) |
| Altman-Z'' Score: -5.14 = D |
Beneish M -2.42
| DSRI: 1.14 (Receivables 125.9m/107.2m, Revenue 1.01b/973.7m) |
| GMI: 0.82 (GM 53.23% / 43.69%) |
| AQI: 2.45 (AQ_t 0.09 / AQ_t-1 0.04) |
| SGI: 1.03 (Revenue 1.01b / 973.7m) |
| TATA: -0.22 (NI -203.4m - CFO -8.79m) / TA 874.7m) |
| Beneish M-Score: -2.42 (Cap -4..+1) = BBB |
What is the price of TNDM shares?
Over the past week, the price has changed by -0.54%, over one month by -6.77%, over three months by +39.90% and over the past year by -44.81%.
Is TNDM a buy, sell or hold?
- StrongBuy: 6
- Buy: 4
- Hold: 10
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the TNDM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26 | 29.2% |
| Analysts Target Price | 26 | 29.2% |
| ValueRay Target Price | 18.8 | -6.5% |
TNDM Fundamental Data Overview February 02, 2026
P/S = 1.3392
P/B = 10.1475
Revenue TTM = 1.01b USD
EBIT TTM = -197.1m USD
EBITDA TTM = -179.7m USD
Long Term Debt = 309.6m USD (from longTermDebt, last quarter)
Short Term Debt = 21.3m USD (from shortTermDebt, last quarter)
Debt = 449.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 357.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.48b USD (1.35b + Debt 449.3m - CCE 319.1m)
Interest Coverage Ratio = -25.21 (Ebit TTM -197.1m / Interest Expense TTM 7.82m)
EV/FCF = -58.86x (Enterprise Value 1.48b / FCF TTM -25.1m)
FCF Yield = -1.70% (FCF TTM -25.1m / Enterprise Value 1.48b)
FCF Margin = -2.50% (FCF TTM -25.1m / Revenue TTM 1.01b)
Net Margin = -20.20% (Net Income TTM -203.4m / Revenue TTM 1.01b)
Gross Margin = 53.23% ((Revenue TTM 1.01b - Cost of Revenue TTM 471.0m) / Revenue TTM)
Gross Margin QoQ = 53.88% (prev 52.29%)
Tobins Q-Ratio = 1.69 (Enterprise Value 1.48b / Total Assets 874.7m)
Interest Expense / Debt = 0.46% (Interest Expense 2.06m / Debt 449.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -155.7m (EBIT -197.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 616.9m / Total Current Liabilities 252.5m)
Debt / Equity = 3.38 (Debt 449.3m / totalStockholderEquity, last quarter 133.0m)
Debt / EBITDA = -1.99 (negative EBITDA) (Net Debt 357.3m / EBITDA -179.7m)
Debt / FCF = -14.22 (negative FCF - burning cash) (Net Debt 357.3m / FCF TTM -25.1m)
Total Stockholder Equity = 171.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.20% (Net Income -203.4m / Total Assets 874.7m)
RoE = -118.8% (Net Income TTM -203.4m / Total Stockholder Equity 171.2m)
RoCE = -41.00% (EBIT -197.1m / Capital Employed (Equity 171.2m + L.T.Debt 309.6m))
RoIC = -31.12% (negative operating profit) (NOPAT -155.7m / Invested Capital 500.4m)
WACC = 7.76% (E(1.35b)/V(1.80b) * Re(10.23%) + D(449.3m)/V(1.80b) * Rd(0.46%) * (1-Tc(0.21)))
Discount Rate = 10.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.73%
Fair Price DCF = unknown (Cash Flow -25.1m)
EPS Correlation: 3.12 | EPS CAGR: 3.39% | SUE: 0.56 | # QB: 0
Revenue Correlation: 59.60 | Revenue CAGR: 4.68% | SUE: 0.28 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.42 | Chg30d=-0.004 | Revisions Net=-2 | Analysts=18
EPS next Year (2026-12-31): EPS=-0.97 | Chg30d=+0.001 | Revisions Net=-2 | Growth EPS=+55.1% | Growth Revenue=+10.1%